4-chloro-5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidine | 637352-97-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-chloro-5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidine
• CAS: 637352-97-7
• 化学式: C₁₂H₈ClF₃N₂
• mdl: MFCD21040581
• 分子量: 272.657
• InChiKey: FWHNFPGLIDMZBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-chloro-5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidine 、 Ethyl {4-[(butylamino)methyl]-2-methylphenoxy}acetate 在 N,N-二异丙基乙胺 作用下， 反应 18.0h， 生成 ethyl {4-[(butyl{5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino)methyl]-2-methylphenoxy}acetate
  参考文献：
  名称：

  [EN] PROPIONIC ACID DERIVATIVES AND THEIR USE AS HPPARS ACTIVATORS
  [FR] COMPOSÉS CHIMIQUES

  摘要：

  公开号：

  WO2004000762A3
• 作为产物：
  描述：

  4,6-二氯-5-甲基嘧啶 、 4-三氟甲基苯硼酸 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 18.0h， 生成 4-chloro-5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidine
  参考文献：
  名称：

  [EN] PROPIONIC ACID DERIVATIVES AND THEIR USE AS HPPARS ACTIVATORS
  [FR] COMPOSÉS CHIMIQUES

  摘要：

  公开号：

  WO2004000762A3

文献信息

• Amino-heterocycles as vr-1 antagonists for treating pain
  申请人：Blurton Peter

  公开号：US20060040947A1

  公开（公告）日：2006-02-23

  the present invention provides a compound of formula (I): wherein V represents NR 5 , O, S, SO or S(O) 2 ; W and X each independently represent CH or N; Y represents N, CH or C—Ar 2 , with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C—Ar 2 , with the proviso that when Y is N or CH then Z is C—Ar 2 , and with the further proviso that when Y is C—Ar 2 then Z is CH; Ar 1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar 2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R 1 represents halogen, hydroxy, oxo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, hydroxyC 1-6 alkoxy, C 3-7 cycloalkyl, C 3-7 cycloalkoxy, C 3-5 cycloalkylC 1-4 alkyl, cyano, nitro, SR 6 , SOR 6 , SO 2 R 6 , COR 6 , NR 3 COR 6 , CONR 3 R 4 , NR 3 SO 2 R 6 , SO 2 NR 3 R 4 , —(CH 2 ) m carboxy, esterified —(CH 2 ) m carboxy or —(CH 2 ) m NR 3 R 4 ; R 2 represents hydrogen, halogen, hydroxy, C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy or haloC 1-6 alkoxy; R 3 and R 4 are each independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl or fluoroC 1-6 alkyl; or R 3 and R 4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C 1-4 alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O) 2 , or NR 5 ; R 5 represents hydrogen, C 1-4 alkyl, hydroxyC 1-4 alkyl or C 1-4 alkoxyC 1-4 alkyl; R 6 represents hydrogen, C 1-6 alkyl, fluoroC 1-6 alkyl, C 3-7 cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy or haloC 1-6 alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.

  本发明提供了一种化合物，其化学式为（I）：其中V代表NR5、O、S、SO或S（O）2；W和X各自独立地代表CH或N；Y代表N、CH或C-Ar2，但至少有一个，但不超过两个，W、X和Y是N；Z代表CH或C-Ar2，但当Y为N或CH时，Z为C-Ar2，且进一步规定当Y为C-Ar2时，Z为CH；Ar1代表一个融合的9或10个成员的杂双环环系统，其中包含从氮、氧和硫中选择的一个、两个、三个或四个杂原子，其中至少一个环为芳香环；Ar2代表一种芳香环，选择自苯基、吡啶基、嘧啶基和吡啶嗪基，可选地融合和取代；R1代表卤素、羟基、氧代、C1-6烷基、C2-6烯基、C2-6炔基、卤代C1-6烷基、羟基C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、羟基C1-6烷氧基、C3-7环烷基、C3-7环烷氧基、C3-5环烷基C1-4烷基、氰基、硝基、SR6、SOR6、SO2R6、COR6、NR3COR6、CONR3R4、NR3SO2R6、SO2NR3R4、-(CH2)m羧基、酯化的-(CH2)m羧基或-(CH2)mNR3R4；R2代表氢、卤素、羟基、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基、卤代C1-6烷氧基、未取代苯基或取代一个或两个群的苯基，所述群从卤素、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基或卤代C1-6烷氧基中选择；R3和R4各自独立地代表氢、C1-6烷基、C2-6烯基、C2-6炔基、C3-7环烷基或氟代C1-6烷基；或R3和R4及它们所连接的氮原子一起形成4至7个环原子的杂脂环，可选地取代一个或两个群，所述群从羟基或C1-4烷氧基中选择，该环可以选择地包含一个氧原子或硫原子、S（O）、S（O）2或NR5作为其中一个所述环原子；R5代表氢、C1-4烷基、羟基C1-4烷基或C1-4烷氧基C1-4烷基；R6代表氢、C1-6烷基、氟代C1-6烷基、C3-7环烷基、未取代苯基或取代一个或两个群的苯基，所述群从卤素、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基或卤代C1-6烷氧基中选择；m为零或1至4的整数；n为零或1至3的整数；或其药学上可接受的盐、N-氧化物或前药；包含它的制药组合物；它在治疗方法中的用途；用于制造治疗VR-1相关疾病的药物，例如疼痛和/或炎症占主导地位的疾病；以及使用它的治疗方法。
• Chemical compounds
  申请人：Beswick John Paul

  公开号：US20060074111A1

  公开（公告）日：2006-04-06

  A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, Wherein: R 1 and R 2 are independently hydrogen or C 1-3 alkyl; X represents a bond, CH 2 or O; R 3 and R 4 are independently hydrogen, C 1-6 alkyl, OCH 3 , CF 3 , allyl or halogen; X 1 is CH 2 , SO 2 , or CO; R 5 is —C 1-6 alkyl (optionally substituted by C 1-6 alkoxy or C 1-6 alkylthio), —C 2-6 alkenyl, —C 0-6 alkyl phenyl (wherein the phenyl is optionally substituted by one or more CF 3 , halogen, C 1-3 alkyl, C 1-3 alkoxy), —COC 1-6 alkyl, SO 2 C 1-6 alkyl; R 6 is phenyl or a 6 membered heteroaryl group containing 1, 2 or 3 N atoms wherein the phenyl or heteroaryl group is optionally substituted with 1, 2 or 3 moieties selected from the group consisting of C 1-6 alkyl, halogen, —OC 1-6 alkyl, —SO 2 C 1-3 alkyl, phenyl (optionally substituted by one or more groups selected from halogen, CF 3 , C 1-3 alkyl, OC 1-3 alkyl, acetyl, CN).

  化合物的化学式为（I），或其药学上可接受的盐、溶剂化物或可水解酯，其中： R1和R2独立地表示氢或C1-3烷基； X表示键合、CH2或O； R3和R4独立地表示氢、C1-6烷基、OCH3、CF3、烯丙基或卤素； X1表示CH2、SO2或CO； R5表示-C1-6烷基（可选用C1-6烷氧基或C1-6烷基硫氧基取代），-C2-6烯基，-C0-6烷基苯（其中苯环可选用一个或多个CF3、卤素、C1-3烷基、C1-3烷氧基取代），-COC1-6烷基，SO2C1-6烷基； R6表示苯基或含有1、2或3个N原子的6元杂环基团，其中苯基或杂环基团可选用1、2或3个从以下组中选择的基团取代：C1-6烷基、卤素、-OC1-6烷基、-SO2C1-3烷基、苯基（可选用一个或多个从卤素、CF3、C1-3烷基、OC1-3烷基、乙酰、CN中选择的基团取代）。
• PROPIONIC ACID DERIVATIVES AND THEIR USE AS HPPARS ACTIVATORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1513795A2

  公开（公告）日：2005-03-16
• AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP1562934B1

  公开（公告）日：2008-03-26
• US7199239B2
  申请人：——

  公开号：US7199239B2

  公开（公告）日：2007-04-03